Pegylated recombinant human endostatin (Shandong Simcere Medgenn/China Pharmaceutical University)

注射用聚乙二醇化重组人血管内皮抑制素

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePegylated recombinant human endostatin (Shandong Simcere Medgenn/China Pharmaceutical University)
Drug Alias NamePegylated Endostar injectionPEG-Endostar injectionrecombinant human endostatinEndu-PEGSIM-0710
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionAngiogenesis inhibitors
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Simcere Pharmaceutical Co LtdChina Pharmaceutical University
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Xiansheng Medicament Research Co LtdShandong Xiansheng Zaiming Biopharmaceutical Co LtdJiangsu Simcere Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A